Clinical trials: Leishmaniasis, Cutaneous
Leishmaniasis, Cutaneous
Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia
This clinical trial aims to evaluate the effectiveness of combining the standard treatment for complicated cutaneous leishmaniasis (CL), sodium stibogluconate (SSG), with either topical fusidic acid 2% cream or a vehicle cream…
- Trial name
- AIM-CL (NCT06695143)
- Testing
- Fusidic Acid, Vehicle cream
- Where
- 2 sites in Ethiopia
- Volunteers
- 180 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniases
OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients
While there are indications that 28 days of miltefosine is not sufficient for treating CL by L. aethiopica, a better understanding of what happens in terms of parasite clearance and drug dosing is lacking.
- Trial name
- OPTIMILEISH (NCT06514560)
- Testing
- Miltefosine
- Where
- Ethiopia
- Volunteers
- 80 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniasis, American
Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly
A randomized controlled pilot trial with the aim of identifying the dose of liposomal amphotericin B associated with the highest cure rate in Cutaneous Leishmaniasis (CL).
- Trial name
- NCT06449040
- Testing
- Liposomal amphotericin B (AmBisome®)
- Where
- Brazil
- Volunteers
- 28 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Cutaneous Leishmaniasis
Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia
Outcomes of patients receiving SSG and Allopurinol combination have never been documented systematically in Ethiopia. Therefore, it is not known how effective this combination is.
- Trial name
- NCT04699383
- Testing
- Sodium Stibogluconate with allopurinol
- Where
- Ethiopia
- Volunteers
- 105 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).
- Trial name
- NCT00508963
- Testing
- sodium stibogluconate (Pentostam)
- Where
- United States
- Sponsor
- University of California, San Francisco
Leishmaniasis, Cutaneous Leishmaniases
A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies
The disease leishmaniasis mainly occurs in hot and tropical countries, affects millions of people and causes around 20,000 deaths across the world every year.
- Conditions
- Leishmaniasis, Cutaneous Leishmaniases, Insect Bites
- Trial name
- LEISHChallenge (NCT04512742)
- Testing
- biting by Phlebotomus duboscqi infected with Leishmania major
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of York
Leishmaniasis, Cutaneous
Intralesional Voriconazole, or Intralesional Cryotherapy, or Oral Doxycycline in the Treatment of Cutaneous Leishmaniasis
Leishmaniasis is a vector-borne disease caused by obligate, intracellular protozoa of the genus Leishmania and transmitted by phlebotomine sandflies.
- Trial name
- NCT05708625
- Testing
- Intralesional Sodium stibogluconate, Intralesional Cryotherapy, Intralesional Voriconazole
- Where
- Libya
- Volunteers
- 136 people
- Sponsor
- Zagazig University
Cutaneous Leishmaniasis, American
Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis
Phase 2/3 randomized and controlled clinical trial, which will evaluate the effectiveness of the association meglumine antimoniate (Glucantime) with tofacitinib in the cure of CL and the capacity of this association to reduce the…
- Trial name
- CLTofa23 (NCT06011343)
- Testing
- Oral tofacitinib, Parenteral meglumine antimoniate
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Cutaneous Leishmaniasis, American
Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.
This project is composed of a phase I study with the purpose of evaluating adverse reactions and the best dose to be used of Sm29 and a phase II randomized controlled study with 3 arms with the purpose of comparing the efficacy…
- Trial name
- NCT06000514
- Testing
- Sm29 Protein, Schistosoma Mansoni, Pentavalent antimony (Sbv)
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Leishmaniasis, Cutaneous
A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL
This trial is designed to assess the therapeutic efficacy and safety of CHAd63-KH, a new candidate Leishmania vaccine, in patients with persistent PKDL.
- Trial name
- NCT03969134
- Testing
- ChAd63-KH
- Where
- Sudan
- Volunteers
- 86 people
- Sponsor
- University of York
Cutaneous Leishmaniases
Cutaneous Leishmaniasis Diagnostic Study
The performance of the CL Detect Rapid test will be tested in individuals with suspected cutaneous leishmaniasis in Ethiopia using both skin slit and dental broach samples against a combined reference of microscopy and PCR.
- Trial name
- NCT03837431
- Testing
- Skin slit, Dental broach, Tape disc
- Where
- Ethiopia
- Volunteers
- 351 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Visceral Leishmaniasis, Cutaneous Leishmaniases
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects
This study will evaluate how the test medicine DNDI-0690 is taken up and broken down by the body and will also look at the safety and tolerability of the test medicine after a single dose.
- Trial name
- NCT03929016
- Testing
- DNDI-0690
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Leishmaniasis, Cutaneous, Insect Bites
A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol
The disease leishmaniasis mainly occurs in hot and tropical countries, affects millions of people and causes around 20,000 deaths across the world every year.
- Trial name
- FLYBITE (NCT03999970)
- Testing
- Sand fly bite
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of York
Cutaneous Leishmaniasis, American
Feasibility and Usability of Mobile Applications for Monitoring Cutaneous Leishmaniasis Treatment in Colombia
An effectiveness-implementation sequential explanatory hybrid design type 2 was performed in two rural communities of Colombia. A quasi-experimental study with historical control (standard of care) was designed to estimate the…
- Trial name
- NCT05533736
- Testing
- Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis
- Where
- Colombia
- Volunteers
- 105 people
- Sponsor
- Centro Internacional de Entrenamiento e Investigaciones Médicas
Cutaneous Leishmaniases, Treatment Adherence
Study of Cases of Cutaneous Leishmaniasis Treated With Miltefosine in French Guiana, Retrospective Study
Miltefosine is the only oral treatment currently available for Cutaneous Leishmaniasis. Despite several reports of good efficiency in other countries of South America, miltefosine remains limited to a compassionate use in France.
- Conditions
- Cutaneous Leishmaniases, Treatment Adherence, Primary Health Care, Drug Evaluation
- Trial name
- MILT2022 (NCT05493059)
- Testing
- Data collection, Questionnaires
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier de Cayenne
Leishmaniasis, Cutaneous
Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.
Cutaneous Leishmaniasis (CL) is a parasitic disease caused by more than 15 different species of the protozoan parasite Leishmania.
- Trial name
- Curaleish (NCT04072874)
- Testing
- Experimental topical (Curaleish Topical)
- Where
- Colombia
- Sponsor
- Universidad de Antioquia
Leishmaniasis, Cutaneous
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
Leishmaniasis is considered by the WHO as emerging and uncontrolled diseases. They are the second leading cause of death and the fourth leading cause of morbidity in tropical diseases.
- Trial name
- Asymptoleish (NCT03303898)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Leishmaniasis, Cutaneous
Investigation of an Outbreak Situation of Cutaneous Leishmaniasis Among Military Personnel in French Guiana (CEFELEISH)
Clinical, epidemiological, therapeutic and microbiological investigation of an outbreak of cutaneous Leishmaniasis that occurred among military personnel in French Guiana in 2020.
- Trial name
- CEFELEISH (NCT04888130)
- Testing
- Phylogenetic Analysis, Data collection
- Where
- French Guiana
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier de Cayenne
Leishmaniasis, Cutaneous
Development of Topical Herbal Formulations for Treatment of Cutaneous Leishmaniasis
Infections due to protozoa of the genus Leishmania are a major worldwide skin problem, with high endemicity in developing countries including Pakistan.
- Trial name
- NCT04841239
- Testing
- Herbal topical formulation
- Where
- Pakistan
- Volunteers
- 78 people
- Sponsor
- Jinnah Sindh Medical University
Cutaneous Leishmaniases
Diagnosis of Cutaneous Leishmaniasis Using the CL-detect Rapid Test in Travelers and Migrants in Belgium
Cutaneous Leishmaniasis (CL) is a neglected tropical disease which is increasingly seen in travelers and migrants evaluated in travel clinics of non-endemic countries.
- Trial name
- RapidLeish (NCT04001335)
- Testing
- Dental Broach
- Where
- Belgium
- Volunteers
- 6 people
- Sponsor
- Institute of Tropical Medicine, Belgium